Terms: = Lung cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
492 results:
1. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
2. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.
Hussain S; Mursal M; Verma G; Hasan SM; Khan MF
Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235
[TBL] [Abstract] [Full Text] [Related]
3. The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer-bearing mice and patients.
Liu M; Li H; Guo R; Yu X; Li Y
Clin Respir J; 2024 Feb; 18(2):e13738. PubMed ID: 38403875
[TBL] [Abstract] [Full Text] [Related]
4. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
6. Antiangiogenic Action of JZL184 on Endothelial Cells via Inhibition of VEGF Expression in Hypoxic lung cancer Cells.
Wittig F; Pannenberg L; Schwarz R; Bekeschus S; Ramer R; Hinz B
Cells; 2023 Sep; 12(19):. PubMed ID: 37830546
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract] [Full Text] [Related]
8. The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors.
Chen Y; Lin Y; Guan S; Zhao Z; Lin D; Guan J; Zhou C; Liu J; Cao X; Lin Z; Chen D; Shang J; Zhang W; Chen H; Chen L; Ma S; Gu L; Zhao J; Huang M; Wang X; Long H
Drug Metab Dispos; 2023 Dec; 51(12):1583-1590. PubMed ID: 37775332
[TBL] [Abstract] [Full Text] [Related]
9. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
10. In vivo self-assembly and delivery of vegfr2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract] [Full Text] [Related]
11. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR; Lawrenson JG
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD000254. PubMed ID: 37702300
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
[TBL] [Abstract] [Full Text] [Related]
13. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract] [Full Text] [Related]
14. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
15. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer.
JiaXin Y; XiaoFeng C; PengFei C; Songchen Z; Ziling L
Medicine (Baltimore); 2023 Jun; 102(26):e34143. PubMed ID: 37390276
[TBL] [Abstract] [Full Text] [Related]
16. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.
Khaparkhuntikar K; Maji I; Gupta SK; Mahajan S; Aalhate M; Sriram A; Gupta U; Guru SK; Kulkarni P; Singh PK
J Biomol Struct Dyn; 2024; 42(3):1469-1484. PubMed ID: 37272883
[TBL] [Abstract] [Full Text] [Related]
17. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
[TBL] [Abstract] [Full Text] [Related]
18. Non-Small Cell lung cancer treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.
Król K; Mazur A; Stachyra-Strawa P; Grzybowska-Szatkowska L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982933
[TBL] [Abstract] [Full Text] [Related]
19. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Nakamura A; Yamaguchi O; Mori K; Miura K; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
Eur J Cancer; 2023 May; 184():62-72. PubMed ID: 36905770
[TBL] [Abstract] [Full Text] [Related]
20. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for lung cancer in Mice through Inhibition of PD-L1 Expression.
Wang SS; Liu Y; Zhang XT; Yu DQ
Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182
[TBL] [Abstract] [Full Text] [Related]
[Next]
